All In Biotech

Drug Trial Radar · NCT05472324

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

A Multicenter,Randomized,Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Poorly Controlled Severe Asthma

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

205

Actual

Start

Sep 23, 2022

Primary completion

Mar 5, 2025

Study completion Mar 5, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II, multicenter, double-blind, randomized, parallel group, placebo-controlled clinical study to evaluate the effect of three doses of TQC2731 on Annualized Asthma Exacerbation Rates(AAER) in adult subjects with poor control of severe asthma. It is estimated that 220 subjects will be included. The subjects will receive TQC2731 (70 mg Q4w, 210 mg Q4w, 420 mg Q4w) or placebo (Q4w) administered by Subcutaneous (SC) in the ratio of 1:1:1:1. The study comprised a 5 to 6-week screening period, a 52-week treatment period and a 12-week follow-up period. During the treatment period, the study drug will be administered from day 0 until week 48. The study drug was not administered at the 52nd week.

Conditions

  • Severe Asthma

Interventions

  • TQC2731 injectionDrug

    TQC2731 is a humanized monoclonal antibody based on human thymic stromal lymphopoietin (TSLP) sequence.

  • PlaceboDrug

    The drug is a placebo Comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual Asthma Exacerbation RateTime frame: Baseline up to Study Week 64

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GUANGZHOU FIRST PEOPLE's HOSPITAL

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.